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In a patient suffering from peripheral neuropathy due to neurolymphomatosis, fused PET–CT imaging,
performed on a novel in-line PET–CT system, showed multiple small nodular lesions extending along
the peripheral nerves corresponding to an early relapse of a transformed B-cell non-Hodgkin’s
lymphoma.
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Introduction
Non-Hodgkin’s lymphoma involving the peripheral nervous
system is a rare cause of peripheral neuropathy. The differen-
tial diagnosis comprises herpes zoster infection, vinca
alkaloid toxicity, compression or infiltration of nerve roots,
lymphoma-associated vasculitis and systemic amyloidosis
[1]. In the present case we demonstrate that co-registered
imaging with positron-emission tomography (PET) and com-
puted tomography (CT), in a novel in-line PET–CT scanner,
represents a valuable method to visualize peripheral nerve
involvement in an early relapsed aggressive non-Hodgkin’s
lymphoma.
Case report
A 65-year-old woman was admitted to the hospital because of
progressive motor and sensory impairment in her right arm.
Nine years previously, the patient had undergone radiotherapy
(36 Gy) for a stage IA follicular B-cell non-Hodgkin’s
lymphoma in the left lower pelvis. Thereafter, the patient
remained in complete remission. Eight months ago, the
woman was admitted to the hospital for abdominal discomfort
associated with increasing weakness of the right leg over a
course of 3 months. On physical examination, a large mass
was noted in the right abdomen and edema of the lower right
extremity. Lactate dehydrogenase was 1880 U/l (<540) and no
pathological protein was detected in the serum immune
electrophoresis. A CT scan of the abdomen and pelvis showed
a large abdominal/pelvic mass (18 × 18 × 12 cm); the histo-
pathological examination of a biopsy revealed a diffuse large
B-cell non-Hodgkin’s lymphoma. No hepatosplenomegaly,
lymphadenopathy or bone marrow infiltration were found.
The weakness of the right leg was due to an obturator mono-
neuropathy. After six cycles of CHOP chemotherapy (cyclo-
phosphamide, doxorubicin, vincristine, prednisone), magnetic
resonance imaging (MRI) revealed no residual tumor. How-
ever, the weakness of the right leg improved only slightly.
Two weeks after the last systemic chemotherapeutic cycle,
the patient complained of painful sensations and progressive
weakness in the extensors of the fingers of the right hand. A
neurologic examination revealed the beginnings of atrophy in
all the small muscles of the right hand. An electromyographic
examination showed a small median-nerve compound muscle
action-potential with delayed distal motor latency. The ulnar-
sensory and motor-nerve conduction signals were patho-
logical with high spontaneous activity potentials, consistent
with a severe proximal axonal sensomotoric neuropathy of the
ulnar and median nerve. The fusion of PET and CT scans
showed a number of small lesions along the plexus brachialis
and vessel-nerve bundle of the right arm (Figures 1 and 2).
Due to the rapid progression of neurologic symptoms, percu-
taneous radiotherapy was performed involving the right axil-
lary and brachial region (total 40 Gy). However, the patient’s
disease progressed rapidly with an extensive increase in 2-[F-
18]-fluoro-2-deoxy-D-glucose (FDG) uptake in the right upper
arm and both axillary regions (Figures 3 and 4). After two
cycles of salvage therapy (rituximab-ifosfamide, cytarabin,
etoposide) the lymphoma showed impressive clinical regres-
sion. However, no recovery of the associated neuropathy
could be observed. After four cycles of salvage chemotherapy
the combined PET–CT showed complete regression of all
lymphoma manifestations. Unfortunately, the associated
neuropathy of the right arm persisted.
Materials and methods
A fusion of PET and CT scans was performed on an in-line PET–CT
system to confirm the hypothesis that the early relapse of the lymphoma
with extension along the peripheral nerves was underlying the peripheral
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neuropathy. Imaging and data acquisition was performed on a novel com-
bined PET–CT in-line system (Discovery LS; GE Medical Systems,
Waukesha, WI, USA), combining the ability to acquire CT images and
PET data from the same patient in one session. A GE Advance NXi PET
scanner and a multislice helical CT (LightSpeed plus) were integrated in
this dedicated system. The axes of both systems were mechanically
aligned to coincide perfectly. Sixty to 120 min after i.v. injection of
10 mCi of FDG, emission data were acquired at six incremental table
positions, each 146 mm wide, thereby covering 867 mm of table travel.
For each position, 35 two-dimensional non-attenuation-corrected scans
were obtained simultaneously over a 4 min period. CT data were used for
attenuation correction. Therefore, data acquisition was performed within
25 min to cover from the scull-base to the level of the pelvic floor.
Viewing of co-registered images was performed with dedicated software
(eNTEGRA, ELGEMS, Haifa, Israel).
Discussion
Peripheral nervous system involvement of lymphoma is rare.
Experience with lymphoma presenting as a solitary tumor of a
peripheral nerve and the dissemination of lymphoma extend-
ing along peripheral nerves is limited to few case reports
[2, 3]. The clinicopathologic syndrome of neurolymphomato-
sis (NL), or lymphomatous infiltration of peripheral nerves, is
a relatively rare condition that usually develops in patients
with widespread non-Hodgkin’s lymphoma and may be the
first manifestation or the sole relapse site [4, 5]. Neuro-
lymphomatosis-related painful polyneuropathy has been
described during or immediately after a course of systemic
chemotherapy and despite a good response of the systemic
disease [5], similar to the clinical presentation in our patient.
Differential diagnoses include reactivation of latent herpes
zoster virus, which usually shows a dermatomal distribution
associated with severe pain, but which may also lead to sys-
temic manifestation [6]. Furthermore vinca alkaloids, which
are commonly used drugs in lymphoma treatment, as well as
radiation plexopathy, may cause peripheral neuropathy [7].
Lymphoma-associated vasculitis and systemic amyloidosis
Figure 1. Maximum intensity projection PET image showing a 
contiguous lesion along the plexus brachialis and the vessel-nerve bundle 
of the right arm. A second lesion is seen in the left axillary region.
Figure 2. (A) PET image indicating increased FDG uptake in the medial 
aspect of the arm and enhancement of the heart. (B) Non-enhanced CT 
scans at the same level showing no evidence of a tumor. (C) PET–CT 
fusion shows clear localization of the lesion within the neurovascular 
bundle of the right arm (arrow).
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may present with peripheral neuropathy and can be difficult to
distinguish from nerve root compression or multifocal neo-
plastic infiltration [1, 8–10].
In patients with Morbus Hodgkin and, as recently described,
non-Hodgkin’s lymphoma, who develop neurological symp-
toms, Guillain–Barre syndrome should also be considered
in the differential diagnosis [11]. Diagnosis of NL usually
requires histologic demonstration of infiltrating malignant
lymphocytes in a peripheral nerve. However, nerve biopsy
may fail despite the widespread lymphomatous infiltration of
peripheral nerves [5]. While MRI can be useful in identifying
affected nerves, it may not be sensitive enough for small
lesions [12, 13]. The role of PET in the assessment of non-
Hodgkin’s lymphoma and as a prognostic marker is under
evaluation. Recent reports show encouraging results,
especially in follow-up examinations after chemotherapy
[14–18].
During the early years of clinical tumor imaging with PET
the potential of multi-modality image fusion has been recog-
nized [19]. Meanwhile, several studies have shown that a
combination of PET and CT by software co-registration is
more accurate than CT alone, especially in staging non-small-
cell lung cancer and detection of mediastinal lymph node
metastases [20]. Recently, Townsend et al. [21] introduced a
combined PET–CT scanner, using a low performance helical
CT and a low performance PET scanner, which permits the
acquisition of co-registered PET and CT images in the same
imaging session. Analysis of the results showed an improve-
ment in lesion localization and classification. The technique
used in this case is more advanced since high-end PET and
CT scanners were involved, which allowed for rapid data
acquisition in <30 min. An advantage lies in the higher con-
fidence level of lesion localization that fusion PET–CT may
provide. However, this technique is limited by the nature of
FDG uptake, since inflammatory lesions may show an
increased accumulation of the tracer as well. In this case,
inflammatory changes can be excluded by the clinical course
of the disease.
In conclusion, causes of peripheral neuropathy may be dif-
ficult to distinguish during progressive disease and therapy of
aggressive lymphoma. The fusion of PET and CT data may
provide a novel tool for imaging NL in relapse of aggressive
Figure 3. Maximum intensity projection PET image from the follow-up 
examination, revealing an extensive increase in the tumor burden in the 
right arm and new lesions in the left side.
Figure 4. (A) Axial PET image at the level of the right arm showing an 
increase in FDG uptake in the right arm. (B) In this CT image, a mass is 
seen in the neurovascular bundle, which corresponds to the FDG uptake 
as proven by (C) the fused PET–CT image (arrow).
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non-Hodgkin’s lymphoma and prompt therapeutic implica-
tions without the risk of invasive manoeuvers.
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